A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine

Robert A. Smith, George J. Klarmann, Kirsten M. Stray, Uta K. Von Schwedler, Raymond F. Schinazi, Bradley D. Preston, Thomas W. North

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

A P157S mutation in the reverse transcriptase (RT) of human immunodeficiency virus type 1 conferred fivefold resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine in cell culture. Interestingly, the P157S mutation resulted in increased sensitivity (two- to threefold) to 3'-azido-3'- deoxythymidine (AZT) and to (R)-9-(2-phosphonyimethoxypropyl)adenine (PMPA). A similar increase in susceptibility to AZT and to PMPA was also conferred by the M184V mutation in RT.

Original languageEnglish (US)
Pages (from-to)2077-2080
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume43
Issue number8
StatePublished - Aug 1999

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-β-2',3'- dideoxy-3'-thiacytidine'. Together they form a unique fingerprint.

Cite this